LN 144

Drug Profile

LN 144

Alternative Names: Autologous T-cell therapy - Iovance Biotherapeutics; Contego; LN144; TILs - Iovance Biotherapeutics; Tumour infiltrating lymphocytes - Iovance Biotherapeutics

Latest Information Update: 05 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer H. Lee Moffitt Cancer Center and Research Institute; Iovance Biotherapeutics; National Cancer Institute (USA)
  • Class Antineoplastics; Cell therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Cell replacements; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant melanoma

Most Recent Events

  • 27 Jun 2017 Lion Biotechnologies is now called Iovance Biotherapeutics
  • 13 Jun 2017 LN 144 is still in phase I trials for Malignant-melanoma(Combination therapy, First-line therapy, Metastatic disease) in USA (IV, Infusion) (NCT01701674)
  • 05 Jun 2017 Efficacy data from a phase II trial in Malignant melanoma presented at the annual meeting of American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top